Holders — by stockHoldings — by fund
ACUTA CAPITAL PARTNERS, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001582844
$143.5M
disclosed book value
23
positions
19.3%
largest position share
Positions, as of 2026-06-30
top 23 of 23 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | PRAXPRAXIS PRECISION MEDICINES I | 82,796 | $27.7M | 19.3% |
| 2 | WHWKWHITEHAWK THERAPEUTICS INC | 4.7M | $21.5M | 15% |
| 3 | TNGXTANGO THERAPEUTICS INC | 390,949 | $12.2M | 8.5% |
| 4 | STROSUTRO BIOPHARMA INC | 270,251 | $9.0M | 6.3% |
| 5 | AVBPARRIVENT BIOPHARMA INC | 218,694 | $7.6M | 5.3% |
| 6 | FDMT4D MOLECULAR THERAPEUTICS INC | 507,801 | $6.8M | 4.7% |
| 7 | DRUGBRIGHT MINDS BIOSCIENCES INC | 92,745 | $6.5M | 4.5% |
| 8 | OCULOCULAR THERAPEUTIX INC | 532,481 | $5.2M | 3.6% |
| 9 | ERASERASCA INC | 265,199 | $4.9M | 3.4% |
| 10 | SRZNSURROZEN INC | 173,395 | $4.5M | 3.1% |
| 11 | ARGXARGEN SE - ADR | 4,705 | $4.4M | 3% |
| 12 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 215,652 | $4.2M | 2.9% |
| 13 | DSGNDESIGN THERAPEUTICS INC | 282,564 | $4.1M | 2.8% |
| 14 | NERVMINERVA NEUROSCIENCES | 709,500 | $3.9M | 2.7% |
| 15 | TSHATAYSHA GENE THERAPIES INC | 561,808 | $3.8M | 2.7% |
| 16 | AVLNAVALYN PHARMA INC | 115,000 | $3.8M | 2.6% |
| 17 | AVTXAVALO THERAPEUTICS INC | 186,308 | $3.4M | 2.4% |
| 18 | AMLXAMYLYX PHARMACEUTICALS INC | 168,115 | $3.0M | 2.1% |
| 19 | ARTVARTIVA BIOTHERAPEUTICS INC | 260,416 | $2.5M | 1.8% |
| 20 | CMPXCOMPASS THERAPEUTICS INC | 595,213 | $1.3M | 0.9% |
| 21 | UTHRUNITED THERAPEUTICS CORP | 2,224 | $1.2M | 0.8% |
| 22 | CTNMCONTINEUM THERAPEUTICS INC-A | 63,095 | $1.0M | 0.7% |
| 23 | LBRXLB PHARMACEUTICALS INC | 28,919 | $938,566 | 0.7% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.